Compare Rivian Automotive, Inc. (RIVN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rivian Automotive, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Rivian Automotive, Inc. trades at $16.03 (market cap $23.41B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 5.7× Rivian Automotive, Inc.'s market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals.
| RIVN | VRTX | |
|---|---|---|
Market Cap | $23.41B | $134.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $22.45 | $557.96 |
52-Week Low | $12.50 | $376.62 |
Enterprise Value | $23.45B | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rivian Automotive (RIVN) trades at $16.17, up 2.73% today, with a bullish technical signal from moving averages and a consensus analyst price target of $18.70. The company shows improving financial trends, with revenue growing to $5.39 billion in 2025 and narrowing net losses, though it remains unprofitable. Recent news highlights strong R2 SUV demand and production ramp-up, but cash flow remains negative, and the CFO departure adds execution risk.
RIVN presents a high-risk, high-reward opportunity for growth investors betting on its EV market execution. Upside hinges on successful R2 scaling and path to profitability, while risks include cash burn, competition, and macroeconomic pressures on EV demand. Analyst sentiment is cautiously optimistic with 48% buy ratings.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
